ARQT Stock Summary and Trading Ideas (Arcutis Biotherapeutics | NASDAQ:ARQT)

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.

As of March 31, 2026, ARQT stock price climbed to $23.56 with 1,996,099 million shares trading.

ARQT has a beta of 0.62, meaning it tends to be less sensitive to market movements. ARQT has a correlation of 0.04 to the broad based SPY ETF.

ARQT has a market cap of $2.89 billion. This is considered a Mid Cap stock.

Last quarter Arcutis Biotherapeutics reported $130 million in Revenue and $.13 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.06.

In the last 3 years, ARQT traded as high as $31.77 and as low as $1.76.

The top ETF exchange traded funds that ARQT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

ARQT has outperformed the market in the last year with a price return of +49.8% while the SPY ETF gained +18.4%. However, in the short term, ARQT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -16.1% vs -5.1% return in SPY. But in the last 2 weeks, ARQT shares have fared better than the market returning +3.5% compared to SPY -2.5%.

ARQT support price is $20.68 and resistance is $21.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT shares will trade within this expected range on the day.